Cargando…
New treatments for myasthenia: a focus on antisense oligonucleotides
Autoimmune myasthenia gravis (MG) is a neuromuscular disorder caused by autoantibodies directed against the acetylcholine receptor (AChR). Current symptomatic therapy is based on acetylcholinesterase (AChE) drugs. The available long-term current therapy includes steroids and other immunomodulatory a...
Autores principales: | Angelini, Corrado, Martignago, Sara, Bisciglia, Michela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546757/ https://www.ncbi.nlm.nih.gov/pubmed/23341732 http://dx.doi.org/10.2147/DDDT.S25716 |
Ejemplares similares
-
P-1
Prognostic factors and course of myasthenia
gravis
por: Albertini, E., et al.
Publicado: (2011) -
A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
por: Kim, Kyuho, et al.
Publicado: (2022) -
P-4
Evaluating therapy outcome in Mysthenia
Gravis
por: Bisciglia, M., et al.
Publicado: (2011) -
Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018) -
Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)